Pfizer struck a landmark deal with the U.S. government granting it a three-year tariff exemption in exchange for commitments to enhance domestic drug manufacturing and implement "most favored nation" pricing for Medicaid sales. This agreement entails $70 billion in planned investment for U.S.-based manufacturing and R&D, alongside direct-to-consumer drug discounts averaging 50%, including an 80% price cut on Eucrisa and 40% on Xeljanz. This move sets a precedent for biopharma pricing and supply chain strategies in the United States.